// App-Quantinova.ai

: Long-term effect of alpha-1-antitrypsin augmentation therapy on the decline of FEV1 in deficient patients

Researchers

Presenter

  • Iris G.M. Schouten

Principal Investigators

  • Marise J. Kasteleyn

  • Robert Bals

  • Alice M. Turner

  • Ilaria Ferrarotti

  • Angelo G. Corsico

  • Beatriz Lara Gallego

  • Marc Miravitlles

  • Robert A. Stockley

  • Jan Stolk

Medical Centers

  • Institute of Child Health, University of Birmingham, Birmingham, United Kingdom

  • Department of Internal Medicine V - Pneumology, Allergology and Critical Care Medicine, University Medical Centre, Saarland University, Homburg/Saar, Germany

  • Center for Diagnosis of Inherited Alpha1-antitrypsin Deficiency, Dept of Internal Medicine and Therapeutics Pneumology Unit, IRCCS San Matteo Hospital Foundation University of Pavia, Pavia, Italy

  • Pneumology Department, Hospital Universitari Vall d’Hebron, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain

  • Respiratory Medicine Department, University Hospital Coventry, Coventry, United Kingdom

  • Lung Investigation Unit, University Hospitals, Birmingham National Health Service Foundation Trust, Queen Elizabeth Hospital, Edgbaston, Birmingham, United Kingdom

  • Department of Urology, Leiden Unviersity Medical Center, Leiden, Netherlands

Locations

  • United Kingdom

  • Germany

  • Italy

  • Netherlands

  • Spain

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

  • Gastroenterology (GU)

  • Genetic Disorder

Disease

  • Alpha-1 antitrypsin (A1AT) deficiency

Biomarkers

  • N/A

Drug/Treatment

  • Alpha 1-Antitrypsin

Outcome

  • N/A

Study Design

  • Multinational

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved